Fibrinogen‑like protein 2 promotes the accumulation of myeloid‑derived suppressor cells in the hepatocellular carcinoma tumor microenvironment

Liu,Bo-Qian; Bao,Zhi-Ye; Zhu,Jia-Yi; Liu,Hao

doi:10.3892/ol.2020.12308

Fibrinogen‑like protein 2 promotes the accumulation of myeloid‑derived suppressor cells in the hepatocellular carcinoma tumor microenvironment

Authors:
- Bo-Qian Liu
- Zhi-Ye Bao
- Jia-Yi Zhu
- Hao Liu
View Affiliations

Affiliations: Department of Transplant and Hepatobilliary Surgery, The First Hospital of China Medical University, Shenyang, Liaoning 110000, P.R. China
Published online on: November 17, 2020 https://doi.org/10.3892/ol.2020.12308
Article Number: 47
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The tumor microenvironment in hepatocellular carcinoma can be classified into cellular and non‑cellular components. Myeloid‑derived suppressor cells (MDSCs) are cellular components of this microenvironment that serve an important role in the progression of hepatocellular carcinoma. Fibrinogen‑like protein 2 (FGL2) has been demonstrated to promote tumor progression by regulating cellular components of the tumor microenvironment in various types of malignant tumor. The present study aimed to determine the expression of FGL2 in hepatocellular carcinoma and its effect on the tumor microenvironment in order to determine novel targets for liver cancer treatment. Immunohistochemistry and reverse transcription quantitative PCR were performed to determine the expression level of FGL2 and the correlation with surface markers of human MDSCs in hepatocellular carcinoma. Furthermore, a mouse hepatocellular carcinoma cell line overexpressing FGL2 was established by stable transfection of a lentivirus expressing FGL2. In addition, fresh bone marrow cells extracted from mouse femurs were in vitro cultured using conditioned medium derived from the cell line overexpressing FGL2. An orthotopic hepatocellular carcinoma mouse model was also established. The results demonstrated that FGL2 expression level in hepatocellular carcinoma tissues was closely associated with tumor size. FGL2 level was positively correlated with the expression level of the MDSC surface markers CD11b and CD33 in hepatocellular carcinoma. The in vitro results demonstrated that FGL2 could maintain the undifferentiated state of bone marrow cells, therefore promoting MDSC accumulation. Furthermore, in the orthotopic hepatocellular carcinoma mouse model, we observed that overexpression of FGL2 could promote tumor growth and significantly increase the number of MDSCs in the tumors and spleen. Taken together, these findings suggested that FGL2 may promote hepatocellular carcinoma tumor growth by promoting the accumulation of MDSCs in the tumor microenvironment.

View Figures

View References

1	An L, Zeng HM, Zheng RS, Zhang SW, Sun KX, Zou XN, Chen R, Wang SM, Gu XY, Wei WW and He J: Liver cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 41:721–727. 2019.(In Chinese). PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Eggert T and Greten TF: Tumor regulation of the tissue environment in the liver. Pharmacol Ther. 173:47–57. 2017. View Article : Google Scholar : PubMed/NCBI
4	Wu T and Dai Y: Tumor microenvironment and therapeutic response. Cancer Lett. 387:61–68. 2017. View Article : Google Scholar : PubMed/NCBI
5	Sevic I, Spinelli FM, Cantero MJ, Reszegi A, Kovalszky I, García MG and Alaniz L: The role of the tumor microenvironment in the development and progression of hepatocellular carcinoma. Hepatocellular Carcinoma [Internet]. Tirnitz-Parker J: Codon Publications; Brisbane (AU): Chapter 2. 2019, simplehttps://www.ncbi.nlm.nih.gov/books/NBK549192/ View Article : Google Scholar
6	Yin Z, Dong C, Jiang K, Xu Z, Li R, Guo K, Shao S and Wang L: Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma. J Hematol Oncol. 12:1012019. View Article : Google Scholar : PubMed/NCBI
7	Thomas H: LSEC stretch promotes fibrosis during hepatic vascular congestion. Nat Rev Gastroenterol Hepatol. 16:262–263. 2019. View Article : Google Scholar : PubMed/NCBI
8	Tesi RJ: MDSC; the most important cell you have never heard of. Trends Pharmacol Sci. 40:4–7. 2019. View Article : Google Scholar : PubMed/NCBI
9	Tahmasebi Birgani M and Carloni V: Tumor microenvironment, a paradigm in hepatocellular carcinoma progression and therapy. Int J Mol Sci. 18:4052017. View Article : Google Scholar
10	Novikova MV, Khromova NV and Kopnin PB: Components of the hepatocellular carcinoma microenvironment and their role in tumor progression. Biochemistry (Mosc). 82:861–873. 2017. View Article : Google Scholar : PubMed/NCBI
11	Condamine T, Mastio J and Gabrilovich DI: Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol. 98:913–922. 2015. View Article : Google Scholar : PubMed/NCBI
12	Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, Gillanders WE, Linehan DC and Goedegebuure P: Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol Immunother. 61:1373–1385. 2012. View Article : Google Scholar : PubMed/NCBI
13	Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S and Srikrishna G: Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 181:4666–4675. 2008. View Article : Google Scholar : PubMed/NCBI
14	Talmadge JE and Gabrilovich DI: History of myeloid-derived suppressor cells. Nat Rev Cancer. 13:739–752. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ugel S, De Sanctis F, Mandruzzato S and Bronte V: Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest. 125:3365–3376. 2015. View Article : Google Scholar : PubMed/NCBI
16	Bergenfelz C and Leandersson K: The generation and identity of human myeloid-derived suppressor cells. Front Oncol. 10:1092020. View Article : Google Scholar : PubMed/NCBI
17	Hsieh CC, Hung CH, Lu L and Qian S: Hepatic immune tolerance induced by hepatic stellate cells. World J Gastroenterol. 21:11887–11892. 2015. View Article : Google Scholar : PubMed/NCBI
18	Xu Y, Fang F, Jiao H, Zheng X, Huang L, Yi X and Zhao W: Activated hepatic stellate cells regulate MDSC migration through the SDF-1/CXCR4 axis in an orthotopic mouse model of hepatocellular carcinoma. Cancer Immunol Immunother. 68:1959–1969. 2019. View Article : Google Scholar : PubMed/NCBI
19	Kumar V, Patel S, Tcyganov E and Gabrilovich DI: The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37:208–220. 2016. View Article : Google Scholar : PubMed/NCBI
20	Yuwaraj S, Ding J, Liu M, Marsden PA and Levy GA: Genomic characterization, localization, and functional expression of FGL2, the human gene encoding fibroleukin: A novel human procoagulant. Genomics. 71:330–338. 2001. View Article : Google Scholar : PubMed/NCBI
21	Marazzi S, Blum S, Hartmann R, Gundersen D, Schreyer M, Argraves S, von Fliedner V, Pytela R and Rüegg C: Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes. J Immunol. 161:138–147. 1998.PubMed/NCBI
22	Yang G and Hooper WC: Physiological functions and clinical implications of fibrinogen-like 2: A review. World J Clin Infect Dis. 3:37–46. 2013. View Article : Google Scholar : PubMed/NCBI
23	Chan CW, Kay LS, Khadaroo RG, Chan MW, Lakatoo S, Young KJ, Zhang L, Gorczynski RM, Cattral M, Rotstein O and Levy GA: Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: Suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. J Immunol. 170:4036–4044. 2003. View Article : Google Scholar : PubMed/NCBI
24	Liu H, Yang PS, Zhu T, Manuel J, Zhang J, He W, Shalev I, Zhang L, Cybulsky MI, Grant DR, et al: Characterization of fibrinogen-like protein 2 (FGL2): Monomeric FGL2 has enhanced immunosuppressive activity in comparison to oligomeric FGL2. Int J Biochem Cell Biol. 45:408–418. 2013. View Article : Google Scholar : PubMed/NCBI
25	Tang M, Cao X, Li P, Zhang K, Li Y, Zheng QY, Li GQ, Chen J, Xu GL and Zhang KQ: Increased expression of fibrinogen-like protein 2 is associated with poor prognosis in patients with clear cell renal cell carcinoma. Sci Rep. 7:126762017. View Article : Google Scholar : PubMed/NCBI
26	Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB and Li S: FGL2 as a multimodality regulator of tumor-mediated immune suppression and therapeutic target in gliomas. J Natl Cancer Inst. 107:djv1372015. View Article : Google Scholar : PubMed/NCBI
27	Zhu Y, Zhang L, Zha H, Yang F, Hu C, Chen L, Guo B and Zhu B: Stroma-derived fibrinogen-like protein 2 activates cancer-associated fibroblasts to promote tumor growth in lung cancer. Int J Biol Sci. 13:804–814. 2017. View Article : Google Scholar : PubMed/NCBI
28	Engers R, Mueller M, Walter A, Collard JG, Willers R and Gabbert HE: Prognostic relevance of Tiam1 protein expression in prostate carcinomas. Br J Cancer. 95:1081–1086. 2006. View Article : Google Scholar : PubMed/NCBI
29	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
30	Vetsika EK, Koukos A and Kotsakis A: Myeloid-derived suppressor cells: Major figures that shape the immunosuppressive and angiogenic network in cancer. Cells. 8:16472019. View Article : Google Scholar
31	Law AMK, Valdes-Mora F and Gallego-Ortega D: Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. 9:5612020. View Article : Google Scholar
32	Tian X, Shen H, Li Z, Wang T and Wang S: Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J Hematol Oncol. 12:842019. View Article : Google Scholar : PubMed/NCBI
33	Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, DeNardo DG, et al: FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell. 17:121–134. 2010. View Article : Google Scholar : PubMed/NCBI
34	Gabrilovich DI, Ostrand-Rosenberg S and Bronte V: Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 12:253–268. 2012. View Article : Google Scholar : PubMed/NCBI
35	Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF and Korangy F: A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4⁺CD25⁺Foxp3⁺ T cells. Gastroenterology. 135:234–243. 2008. View Article : Google Scholar : PubMed/NCBI
36	Wang D, An G, Xie S, Yao Y and Feng G: The clinical and prognostic significance of CD14(+) HLA-DR(−/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. Tumour Biol. 37:10427–10433. 2016. View Article : Google Scholar : PubMed/NCBI
37	Zhang S, Ma X, Zhu C, Liu L, Wang G and Yuan X: The role of myeloid-derived suppressor cells in patients with solid tumors: A meta-analysis. PLoS One. 11:e01645142016. View Article : Google Scholar : PubMed/NCBI
38	Gao XH, Tian L, Wu J, Ma XL, Zhang CY, Zhou Y, Sun YF, Hu B, Qiu SJ, Zhou J, et al: Circulating CD14⁺ HLA-DR^−/low myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. Hepatol Res. 47:1061–1071. 2017. View Article : Google Scholar : PubMed/NCBI
39	Mizukoshi E, Yamashita T, Arai K, Terashima T, Kitahara M, Nakagawa H, Iida N, Fushimi K and Kaneko S: Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Immunol Immunother. 65:715–725. 2016. View Article : Google Scholar : PubMed/NCBI
40	Zhang X, Fu X, Li T and Yan H: The prognostic value of myeloid derived suppressor cell level in hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 14:e02253272019. View Article : Google Scholar : PubMed/NCBI
41	Liu H, Shalev I, Manuel J, He W, Leung E, Crookshank J, Liu MF, Diao J, Cattral M, Clark DA, et al: The FGL2-FcgammaRIIB pathway: A novel mechanism leading to immunosuppression. Eur J Immunol. 38:3114–3126. 2008. View Article : Google Scholar : PubMed/NCBI
42	Morris AB, Farley CR, Pinelli DF, Adams LE, Cragg MS, Boss JM, Scharer CD, Fribourg M, Cravedi P, Heeger PS and Ford ML: Signaling through the inhibitory Fc receptor FcgammaRIIB induces CD8⁺T cell apoptosis to limit T cell immunity. Immunity. 52:136–150.e6. 2020. View Article : Google Scholar : PubMed/NCBI
43	Selzner N, Liu H, Boehnert MU, Adeyi OA, Shalev I, Bartczak AM, Xue-Zhong M, Manuel J, Rotstein OD, McGilvray ID, et al: FGL2/fibroleukin mediates hepatic reperfusion injury by induction of sinusoidal endothelial cell and hepatocyte apoptosis in mice. J Hepatol. 56:153–159. 2012. View Article : Google Scholar : PubMed/NCBI
44	Takai T, Li M, Sylvestre D, Clynes R and Ravetch JV: FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell. 76:519–529. 1994. View Article : Google Scholar : PubMed/NCBI
45	Ravetch JV and Bolland S: IgG Fc receptors. Annu Rev Immunol. 19:275–290. 2001. View Article : Google Scholar : PubMed/NCBI
46	Pan G, Zhao Z, Tang C, Ding L, Li Z, Zheng D, Zong L and Wu Z: Soluble fibrinogen-like protein 2 ameliorates acute rejection of liver transplantation in rat via inducing Kupffer cells M2 polarization. Cancer Med. 7:3168–3177. 2018. View Article : Google Scholar
47	Jin SJ, Liu Y, Deng SH, Liao LH, Lin TL, Ning Q and Luo XP: Neuroprotective effects of activated protein C on intrauterine inflammation-induced neonatal white matter injury are associated with the downregulation of fibrinogen-like protein 2/fibroleukin prothrombinase and the inhibition of pro-inflammatory cytokine expression. Int J Mol Med. 35:1199–1212. 2015. View Article : Google Scholar : PubMed/NCBI
48	Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A and Tagliamonte M: Immunotherapy in hepatocellular carcinoma. Ann Hepatol. 18:291–297. 2019. View Article : Google Scholar : PubMed/NCBI
49	Brown ZJ and Greten TF: Hepatocellular carcinoma: Translational precision medicine approaches (Internet). Hoshida Y: Immune Therapies Cham (CH): Humana Press. Chapter 12. 2019
50	Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, Rae Z, Hernandez JM, Davis JL, Martin SP, et al: Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell. 36:418–430.e6. 2019. View Article : Google Scholar : PubMed/NCBI
51	Li W, Wang H, Ma Z, Zhang J, Ou-Yang W, Qi Y and Liu J: Multi-omics analysis of microenvironment characteristics and immune escape mechanisms of hepatocellular carcinoma. Front Oncol. 9:10192019. View Article : Google Scholar : PubMed/NCBI
52	Lu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z and Tang W: Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: Challenges and opportunities. Mol Cancer. 18:1302019. View Article : Google Scholar : PubMed/NCBI
53	Liao H, Chen W, Dai Y, Richardson JJ, Guo J, Yuan K, Zeng Y and Xie K: Expression of programmed cell death-ligands in hepatocellular carcinoma: Correlation with immune microenvironment and survival outcomes. Front Oncol. 9:8832019. View Article : Google Scholar : PubMed/NCBI
54	Hilmi M, Vienot A, Rousseau B and Neuzillet C: Immune therapy for liver cancers. Cancers (Basel). 12:772019. View Article : Google Scholar
55	van der Heide D, Weiskirchen R and Bansal R: Therapeutic targeting of hepatic macrophages for the treatment of liver diseases. Front Immunol. 10:28522019. View Article : Google Scholar : PubMed/NCBI
56	Lu LC, Chang CJ and Hsu CH: Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: Current state and future perspectives. J Hepatocell Carcinoma. 6:71–84. 2019. View Article : Google Scholar : PubMed/NCBI
57	Chesney JA, Mitchell RA and Yaddanapudi K: Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy. J Leukoc Biol. 102:727–740. 2017. View Article : Google Scholar : PubMed/NCBI